RR of 9.4% with a median overall survival of 10.4 months. An S is a combination of mitomycin more than second-line therapy showed a 21% reduction in overall RR with a median overall survival of 8.0 months. GSK1838705A ALK inhibitor Systemic chemotherapy in AGC discussion led to an improved survival rate and attenuator Monitoring of symptoms From my BSCalone. The choice of a second line agent h Depends from the first line treatment, which is readily available in different countries L Different. Three randomized studies with 5-FU showed that no combination therapy demonstrated a survival advantage over 5-FU alone, however, improves RR and PFS were observed. The interpretation of these results, especially in the determination of the reference arm, through the region. In Japan, 5-FU alone as a reference arm weight hlt, Because no difference in OS was observed.
Although no OS benefit was demonstrated, the PF, a strong and lasting PFS showed RR, was the backbone of GABA receptor drug chemotherapy in Korea. In most european L European countries A regimen of three drugs, epirubicin, cisplatin and 5-FU on h Ufigsten used, based on a phase III randomized trial comparing ECF with 5-FU, doxorubicin and methotrexate . In Korea, it is common for patients in whom first line palliative chemotherapy second-line chemotherapy in this country was, it is m Possible to detect in patients with AGC good performance because the gastroscopy was readily available and has been a prime Re screening methods used for over 40 years. According to historical data 50% of patients in Korea standard first-line chemotherapy were again U a second-line chemotherapy.
The survival advantage of second-line therapy from the results of Japanese studies, the operating system of second-line treatment in about 12 months was reported to change is the obvious L Longer than the operating system closely for 8 months in the western L. This input is likely to survive low Born differences not only in the criteria of the R Rderungswrdigkeit and baseline characteristics of patients, such as measurable metastatic disease and ethnic differences but also differences between the studies in proportions of populations of patients u again a second-line chemotherapy. A study of second-line chemotherapy in AGC may, the activity t to see the chemotherapy in the treatment of AGC second line in terms of RR, PFS and OS.
These results demonstrate indirectly the r From the second-line chemotherapy for AGC. In addition, salvage chemotherapy is active and well tolerated Is possible, The quality of life can t and clinical outcomes improve in a certain proportion of selected about Hlten patients. In a multicenter, randomized, comparative phase III trial of second-line chemotherapy plus BSC with BSC alone in pretreated AGC was pr in a summary Presents. What is the active ingredient, the second-line chemotherapy in second-line therapy, various drugs such as taxanes, irinotecan, 5-FU Including agents Lich capecitabine and S 1, the officials of platinum to optimize adriamycin, epirubicin and mitomycin C tested. Data on the Net Assets Gene of the second-line agents are not conclusive, because most published studies only a small number of patients and contain heterogeneous populations of patients with locally advanced or metastatic cancer. Paclitaxel, docetaxel and irinotecan were promising drugs that were used ag in combination therapy or as a single tested